<h4>Introduction</h4>Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.